Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anca Dragomir

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Plos One|August 12, 2017
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancerChristina Siesing, Halfdan Sorbye, Anca Dragomir, et al.
Biochemical and Biophysical Research Communications|November 19, 2003
Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed proteinFilipa Mendes, Mónica Roxo Rosa, Anca Dragomir, et al.
International Journal of Environmental Research and Public Health|April 13, 2023
Inequalities in Violent Death across Income Levels among Young Males and Females in Countries of the AmericasOscar J Mujica, Dihui Zhang, Yi Hu, et al.
Oncoimmunology|September 19, 2017
Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in miceJessica Cedervall, Anca Dragomir, Falk Saupe, et al.
Scientific Reports|April 8, 2021
Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancerAlberto Valdés, Athanasios Bitzios, Eszter Kassa, et al.
Acta Oncologica (Stockholm, Sweden)|November 27, 2019
Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian studyArtur Mezheyeuski, Fredrik Ponten, Per-Henrik Edqvist, et al.
Frontiers in Oncology|March 3, 2020
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better <i>BRAF</i> Mutated and a Worse <i>KRAS</i> Mutated SubgroupKristine Aasebø, Anca Dragomir, Magnus Sundström, et al.
Plos One|June 30, 2015
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer CohortHalfdan Sorbye, Anca Dragomir, Magnus Sundström, et al.
Cancer Medicine|May 10, 2019
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patientsKristine Ø Aasebø, Anca Dragomir, Magnus Sundström, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|February 25, 2023
Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour gradePontus Röbeck, Bo Franzén, Rafaele Cantera-Ahlman, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Plos One|August 12, 2017
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancerChristina Siesing, Halfdan Sorbye, Anca Dragomir, et al.
Biochemical and Biophysical Research Communications|November 19, 2003
Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed proteinFilipa Mendes, Mónica Roxo Rosa, Anca Dragomir, et al.
International Journal of Environmental Research and Public Health|April 13, 2023
Inequalities in Violent Death across Income Levels among Young Males and Females in Countries of the AmericasOscar J Mujica, Dihui Zhang, Yi Hu, et al.
Oncoimmunology|September 19, 2017
Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in miceJessica Cedervall, Anca Dragomir, Falk Saupe, et al.
Scientific Reports|April 8, 2021
Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancerAlberto Valdés, Athanasios Bitzios, Eszter Kassa, et al.
Acta Oncologica (Stockholm, Sweden)|November 27, 2019
Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian studyArtur Mezheyeuski, Fredrik Ponten, Per-Henrik Edqvist, et al.
Frontiers in Oncology|March 3, 2020
CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better <i>BRAF</i> Mutated and a Worse <i>KRAS</i> Mutated SubgroupKristine Aasebø, Anca Dragomir, Magnus Sundström, et al.
Plos One|June 30, 2015
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer CohortHalfdan Sorbye, Anca Dragomir, Magnus Sundström, et al.
Cancer Medicine|May 10, 2019
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patientsKristine Ø Aasebø, Anca Dragomir, Magnus Sundström, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|February 25, 2023
Multiplex protein analysis and ensemble machine learning methods of fine needle aspirates from prostate cancer patients reveal potential diagnostic signatures associated with tumour gradePontus Röbeck, Bo Franzén, Rafaele Cantera-Ahlman, et al.
Pageof 5